SG11202109463PA - Crystalline and amorphous forms of n-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2h-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereof - Google Patents

Crystalline and amorphous forms of n-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2h-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereof

Info

Publication number
SG11202109463PA
SG11202109463PA SG11202109463PA SG11202109463PA SG 11202109463P A SG11202109463P A SG 11202109463PA SG 11202109463P A SG11202109463P A SG 11202109463PA SG 11202109463P A SG11202109463P A SG 11202109463PA
Authority
SG
Singapore
Prior art keywords
methyl
ethylpiperazin
indazol
pyrimidin
fluoro
Prior art date
Application number
Other languages
English (en)
Inventor
Michael Greco
Michael Costanzo
Jirong Peng
Don Zhang
Original Assignee
Beta Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beta Pharma Inc filed Critical Beta Pharma Inc
Publication of SG11202109463PA publication Critical patent/SG11202109463PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11202109463P 2019-03-20 2020-03-20 Crystalline and amorphous forms of n-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2h-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereof SG11202109463PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962821141P 2019-03-20 2019-03-20
PCT/US2020/023828 WO2020191283A1 (en) 2019-03-20 2020-03-20 Crystalline and amorphous forms of n-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2h-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
SG11202109463PA true SG11202109463PA (en) 2021-10-28

Family

ID=72519375

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202109463P SG11202109463PA (en) 2019-03-20 2020-03-20 Crystalline and amorphous forms of n-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2h-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereof

Country Status (9)

Country Link
US (1) US20220162185A1 (zh)
EP (1) EP3941472A4 (zh)
JP (1) JP2022525780A (zh)
CN (1) CN113840605B (zh)
AU (1) AU2020240301A1 (zh)
IL (1) IL286012A (zh)
SG (1) SG11202109463PA (zh)
TW (1) TW202102487A (zh)
WO (1) WO2020191283A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3127958A1 (en) * 2019-01-29 2020-08-06 Beta Pharma, Inc. 2h-indazole derivatives as therapeutic agents for brain cancers and brain metastases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106687454B8 (zh) 2014-07-24 2019-08-30 贝达医药公司 作为细胞周期蛋白依赖性激酶(cdk)抑制剂的2h-吲唑衍生物及其医疗用途
CN107428731B (zh) * 2015-03-11 2020-05-05 正大天晴药业集团股份有限公司 作为抗癌药物的取代的2-氢-吡唑衍生物
EP3502103B1 (en) 2016-09-09 2022-04-06 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Crystal form, salt type of substituted 2-hydro-pyrazole derivative and preparation method therefor

Also Published As

Publication number Publication date
WO2020191283A1 (en) 2020-09-24
EP3941472A1 (en) 2022-01-26
CN113840605B (zh) 2024-05-28
AU2020240301A1 (en) 2021-09-23
TW202102487A (zh) 2021-01-16
JP2022525780A (ja) 2022-05-19
US20220162185A1 (en) 2022-05-26
EP3941472A4 (en) 2023-03-15
CN113840605A (zh) 2021-12-24
IL286012A (en) 2021-10-31

Similar Documents

Publication Publication Date Title
EA201992300A1 (ru) КРИСТАЛЛИЧЕСКАЯ ФОРМА 6-(ЦИКЛОПРОПАНКАРБОКСАМИДО)-4-((2-МЕТОКСИ-3-(1-МЕТИЛ-1H-1,2,4-ТРИАЗОЛ-3-ИЛ)ФЕНИЛ)АМИНО)-N-(МЕТИЛ-d3)ПИРИДАЗИН-3-КАРБОКСАМИДА
CY1124078T1 (el) Συνθεσεις που περιλαμβανουν αναστολεα λυσινης ειδικης απομεθυλασης-1 που εχει δακτυλιο πυριμιδινης και χρηση αυτων στη θεραπεια καρκινου
IL287030A (en) New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide as raf inhibitors for cancer therapy
PH12016502461A1 (en) N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide hydrochloride salts
MY179802A (en) Hydrochloride salt form for ezh2 inhibition
EP3807279A4 (en) PHARMACEUTICALLY ACCEPTABLE SALTS OF SEPIAPTERINE
MY183605A (en) Triazine compound and use thereof for medical purposes
MX2021002258A (es) Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
TW201613931A (en) Form crystal of bisulfate of janus kinase (JAK) inhibitor and preparation method thereof
IL288508A (en) History of n-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl)tetrahydro-h2-pyran-4-carboxamide and related compounds as human ctps1 inhibitors to treat proliferative diseases
IL286012A (en) Crystalline and amorphous forms of n-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2h-indazol-5-yl) ) pyrimidine-2-amine and its salts, and preparation methods and therapeutic uses thereof
NZ719688A (en) Pesticidal compositions and related methods
HRP20211868T1 (hr) Derivati aminopiridina i njihova uporaba kao selektivnih inhibitora za alk-2
HK1254731A1 (zh) 用於醫學應用的3-(1，2，4-***並[4，3-a]吡啶-3-基乙炔基)-4-甲基-n-(4-((4-甲基哌嗪-1-基)甲基)-3-三氟甲基苯基)苯甲酰胺的新型結晶鹽形式
MX2020005332A (es) Polimorfos y formas solidas de un compuesto de pirimidinilamino-pirazol y metodos de produccion.
SG11201604517WA (en) Crystalline forms of n-(4-((3-(2-amino-4-pyrimidinyl) - 2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1 -phthalazinamine pharmaceutically acceptable salts and uses thereof
EP3740484A4 (en) 5- (PYRIMIDIN-4-YL) THIAZOL-2-YL-UREA DERIVATIVES AS THERAPEUTICS
WO2015009882A3 (en) Cyano derivatives and their uses
ZA202101652B (en) Novel thiazole derivatives and pharmaceutically acceptable salts thereof
PH12018501314A1 (en) Crystalline forms of hydrochloride salts of thienopyrimidine compound
MX2020009412A (es) Sales y polimorfos de un compuesto imidazopiridinil-aminopiridina sustituido.
AU2018900114A0 (en) 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents
EP3837356A4 (en) AMORPHIC AND CRYSTALLINE FORMS OF VALBENAZINE SALT
EP3414225C0 (en) CRYSTALLINE MODIFICATIONS OF N-(4,5-BISMETHANESULFONYL-2-METHYLBENZOYL)-GUANIDINE HYDROCHLORIDE AND N-(4,5-BISMETHANESULFONYL-2-METHYLBENZOYL)-GUANIDINE SALTS